Sangamo Therapeutics (NASDAQ:SGMO) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report released on Wednesday, Benzinga reports. The firm currently has a $5.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on shares of Sangamo Therapeutics in a research report on Saturday, July 20th. They set a sell rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics presently has an average rating of Hold and an average price target of $5.67.

Sangamo Therapeutics Trading Up 28.7 %

SGMO stock opened at $0.86 on Wednesday. The firm has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.61. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $8.51 million. During the same quarter last year, the business posted $0.12 EPS. Sell-side analysts forecast that Sangamo Therapeutics will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its position in Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the period. Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics by 21.0% in the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the period. Wasatch Advisors LP boosted its stake in shares of Sangamo Therapeutics by 62.4% in the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics during the 1st quarter valued at $331,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.